公开(公告)号：US20240100221A1

公开(公告)日：2024-03-28

申请号：US18359728

申请日：2023-07-26

申请人： Allergan Pharmaceuticals International Limited

发明人： Jens Sommer-Knudsen

IPC分类号： A61L27/22 ,  A61K8/64 ,  A61K8/73 ,  A61L27/20 ,  A61L27/26 ,  A61L27/50 ,  A61L27/58 ,  A61Q19/08 ,  C07K14/765 ,  C07K14/78 ,  C08B11/08 ,  C08B11/12 ,  C08B33/04 ,  C08B37/00 ,  C08B37/02 ,  C08B37/08 ,  C08H1/00 ,  C08H1/06 ,  C08L1/28 ,  C08L3/14 ,  C08L5/00 ,  C08L5/02 ,  C08L5/04 ,  C08L5/08 ,  C08L5/10 ,  C08L89/00 ,  C08L89/06

CPC分类号： A61L27/227 ,  A61K8/64 ,  A61K8/735 ,  A61L27/20 ,  A61L27/22 ,  A61L27/26 ,  A61L27/50 ,  A61L27/58 ,  A61Q19/08 ,  C07K14/765 ,  C07K14/78 ,  C08B11/08 ,  C08B11/12 ,  C08B33/04 ,  C08B37/0009 ,  C08B37/0021 ,  C08B37/0024 ,  C08B37/0033 ,  C08B37/0063 ,  C08B37/0069 ,  C08B37/0072 ,  C08B37/0075 ,  C08B37/0084 ,  C08B37/0096 ,  C08H1/00 ,  C08H1/06 ,  C08L1/28 ,  C08L1/284 ,  C08L1/286 ,  C08L3/14 ,  C08L5/00 ,  C08L5/02 ,  C08L5/04 ,  C08L5/08 ,  C08L5/10 ,  C08L89/00 ,  C08L89/06 ,  A61K2800/91 ,  A61L2400/06 ,  A61L2430/34

摘要： Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

公开(公告)号：US20230406962A1

公开(公告)日：2023-12-21

申请号：US18334456

申请日：2023-06-14

申请人： Shin-Etsu Chemical Co., Ltd.

发明人： Kentaro Miki ,  Takuya Yokosawa

IPC分类号： C08B11/02 ,  C08L1/28

CPC分类号： C08B11/02 ,  C08L1/28

摘要： There are provided hydroxypropyl methyl cellulose (HPMC) having high solubility even when keeping the molar substitution (MS) of hydroxypropoxy groups conventional; and others. More specifically, there are provided HPMC having a molar substitution (MS) of hydroxypropoxy groups of from 0.1 to 0.5, a ratio (referred to as “MF at 3-position/MS”) of 0.12 or more, as calculated by dividing a molar fraction (referred to as “MF at 3-position”) of anhydroglucose units in which only a hydroxy group at the 3-position carbon is substituted with a hydroxypropoxy group and none of hydroxy groups at the 2-position and 6-position carbons is substituted with a hydroxypropoxy group by the molar substitution (referred to as “MS”) of hydroxypropoxy groups, and a viscosity at 20° C. of more than 50 mPa·s and not more than 150000 mPa·s, as determined in a 2% by mass aqueous solution; and others.

公开(公告)号：US20190231662A1

公开(公告)日：2019-08-01

申请号：US16262970

申请日：2019-01-31

申请人： The Procter & Gamble Company

发明人： Janette Villalobos Lingoes ,  Thomas Elliot Rabe ,  Matthew Joseph Linser ,  Travis Kyle Hodgdon ,  Ajay Suthar

IPC分类号： A61K8/29 ,  A61K8/81 ,  A61Q19/00 ,  C08L1/28 ,  C08L33/08 ,  C08L33/26

CPC分类号： A61K8/29 ,  A61K8/19 ,  A61K8/34 ,  A61K8/345 ,  A61K8/8147 ,  A61K8/8152 ,  A61K8/8158 ,  A61K2800/412 ,  A61Q1/02 ,  A61Q19/00 ,  C08L1/28 ,  C08L33/08 ,  C08L33/26 ,  C09D11/322 ,  C09D11/38

摘要： A cosmetic ink composition comprises a particulate material, a polymeric dispersant, a rheology modifier, and a surface tension modifier, wherein the surface tension modifier is selected from the group consisting of C1-C16 alcohols, C5-C18 diols, and mixtures thereof. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a surface tension of from about 20 to about 45 mN/m.

公开(公告)号：US20180179301A1

公开(公告)日：2018-06-28

申请号：US15607561

申请日：2017-05-29

申请人： Zhejiang University of Science and Technology ,  Hangzhou Singclean Medical Products Co., Ltd

发明人： Zhiguo Zhang ,  Wei Huang ,  Yange Suo

IPC分类号： C08B31/18 ,  C08B30/06 ,  A61L15/28 ,  B01J19/00 ,  B01D53/28

CPC分类号： C08B31/18 ,  A61L15/28 ,  A61L2400/04 ,  C08B30/06 ,  C08L1/28

摘要： A method of preparing an oxidized starch haemostatic material, including adding a starch raw material to an external circulation pulsatile reactor; switching on a pump to allow inflow of dry air for drying the raw material; switching on a heat exchanger; vacuumizing the reactor; opening a nitrogen dioxide pipeline and a dry air pipeline; pumping in a mixed gas; controlling temperature at 0-120° C. by the heat exchanger; wherein nitrogen dioxide is contacted with the raw material to trigger a selective oxidation reaction and is continuously recycled; an airflow circulation switch is switched on and off at a pulsating ratio of 1:1-10 to carry out airflow pulsation; stopping inflow of nitrogen dioxide and continuing airflow circulation for 5-30 minutes; after completion of the reaction, adjusting to room temperature; vacuumizing the reactor and treating exhaust gas; allowing nitrogen gas to flow in for rinsing the replaced reactor until completion.

公开(公告)号：US10000692B2

公开(公告)日：2018-06-19

申请号：US14903765

申请日：2013-08-09

申请人： Halliburton Energy Services, Inc.

发明人： Loan Vo ,  Tingji Tang

IPC分类号： C09K8/90 ,  C09K8/68 ,  C08L1/28

CPC分类号： C09K8/90 ,  C08L1/28 ,  C08L1/284 ,  C08L1/286 ,  C09K8/68 ,  C09K2208/24 ,  C09K2208/26

摘要： A method of treating a treatment zone of a subterranean formation penetrated by a wellbore of a well, the method including the steps of: (A) forming a treatment fluid comprising: (i) an aqueous phase comprising water having at least 1,000 ppm total dissolved inorganic salts; (ii) a carboxymethyl hydroxyethyl cellulose, wherein: (a) the carboxymethyl hydroxyethyl cellulose has a carboxymethyl degree of substitution is in the range of about 0.3 to about 0.45 per glucopyranose unit in the polymer; and (b) the carboxymethyl hydroxyethyl cellulose has a hydroxyethyl molecular substitution is in the range of about 2.1 to about 2.8 per glucopyranose unit in the polymer; and (iii) a breaker for the carboxymethyl hydroxyethyl cellulose; and (B) introducing the treatment fluid into the treatment zone. In embodiments, the carboxymethyl hydroxyethyl cellulose may or may not be crosslinked.

公开(公告)号：US09987115B2

公开(公告)日：2018-06-05

申请号：US14007646

申请日：2012-03-30

申请人： Benjamin Y. Arcand ,  James A. Kazmierkoski ,  Dean W. Hacker ,  Emily R. Rolfes Meyering

发明人： Benjamin Y. Arcand ,  James A. Kazmierkoski ,  Dean W. Hacker ,  Emily R. Rolfes Meyering

IPC分类号： A61F2/00 ,  A61B17/04 ,  A61L27/16 ,  A61L27/34 ,  A61L27/56 ,  A61L31/04 ,  A61L31/10 ,  A61L31/14 ,  A61B17/00

CPC分类号： A61F2/0063 ,  A61B17/0401 ,  A61B2017/00805 ,  A61B2017/0427 ,  A61F2/0045 ,  A61F2210/0076 ,  A61L27/16 ,  A61L27/34 ,  A61L27/56 ,  A61L31/048 ,  A61L31/10 ,  A61L31/146 ,  C08L1/28 ,  C08L23/12

摘要： Various embodiments of an implant devices and systems are provided. The implant devices can include a mesh or implant encapsulated or otherwise coated, in whole or in part, with a film or coating. The coating or film can include methylcellulose or ethylcellulose to provide tissue regeneration as a hydrogel, while also providing a stiff polymer film when dry.

公开(公告)号：US20180127515A1

公开(公告)日：2018-05-10

申请号：US15577787

申请日：2016-05-30

申请人： Teknologian tutkimuskeskus VTT Oy

发明人： Jarmo Ropponen ,  Riku Talja ,  Pia Willberg-Keyriläinen ,  Ali Harlin ,  Sari Asikainen ,  Jari Vartiainen

IPC分类号： C08B1/02 ,  C08B3/06 ,  C08B11/02 ,  C08B3/08 ,  C08B3/10 ,  C08B1/06 ,  C08J5/18 ,  C08J7/04

CPC分类号： C08B1/02 ,  C08B1/06 ,  C08B3/06 ,  C08B3/08 ,  C08B3/10 ,  C08B11/02 ,  C08J5/18 ,  C08J7/042 ,  C08J2301/04 ,  C08J2301/10 ,  C08J2301/12 ,  C08J2401/02 ,  C08L1/10 ,  C08L1/28

摘要： According to an example aspect of the present invention, there is provided a method of improving the reactivity and processability of cellulose in order to utilize cheap and easily available raw material and obtain excellent performance for biomaterial manufacturing.

公开(公告)号：US09963534B2

公开(公告)日：2018-05-08

申请号：US15367460

申请日：2016-12-02

申请人： Akzo Nobel Chemicals International B.V.

发明人： Klin Aloysius Rodrigues ,  Anthony John Adamo ,  Samuel Anthony Vona, Jr.

IPC分类号： C08F2/00 ,  C08F20/10 ,  C08F251/00 ,  C08F251/02 ,  C08L1/02 ,  C08L1/28 ,  C08L3/02 ,  C08L3/04 ,  C08L3/10 ,  C08L5/16 ,  C08L33/06 ,  C09D133/02 ,  C09D133/26 ,  C09D135/00 ,  C09D151/02 ,  A61Q19/00 ,  A61K8/81 ,  C09D7/00 ,  A61K8/91 ,  A61Q5/02 ,  C08L51/02

CPC分类号： C08F251/00 ,  A61K8/8135 ,  A61K8/8152 ,  A61K8/8158 ,  A61K8/91 ,  A61K2800/48 ,  A61K2800/546 ,  A61K2800/548 ,  A61Q5/02 ,  A61Q19/00 ,  C08F251/02 ,  C08L1/02 ,  C08L1/28 ,  C08L1/284 ,  C08L1/286 ,  C08L3/02 ,  C08L3/04 ,  C08L3/10 ,  C08L5/16 ,  C08L33/064 ,  C08L51/02 ,  C08L2201/52 ,  C09D7/43 ,  C09D133/02 ,  C09D133/26 ,  C09D135/00 ,  C09D151/02 ,  C08L33/08 ,  C08L33/10 ,  C08L33/12 ,  C08L33/26 ,  C08L5/00 ,  C08L3/00

摘要： Polysaccharide alkali swellable rheology modifiers include an emulsion polymer including at least one polysaccharide portion and at least one synthetic portion wherein the at least one synthetic portion is obtained from at least one anionic ethylenically unsaturated monomer, at least one nonionic ethylenically unsaturated monomer or a combination thereof, wherein at least one of the nonionic ethylenically unsaturated monomers is a hydrophobic ethylenically unsaturated monomer, as well as methods of making polysaccharide alkali swellable rheology modifiers.

公开(公告)号：US09932488B2

公开(公告)日：2018-04-03

申请号：US14895360

申请日：2014-06-04

申请人： TOSOH CORPORATION

发明人： Masayasu Ito ,  Shinsuke Toyomasu ,  Takahiro Kitagawa

IPC分类号： C08L1/26 ,  C08L1/28 ,  C08L35/02 ,  C09D101/28 ,  C08J5/18 ,  C08J7/04 ,  G02B5/30 ,  C08L35/00

CPC分类号： C09D101/28 ,  C08J5/18 ,  C08J7/047 ,  C08J2301/26 ,  C08J2301/28 ,  C08J2331/06 ,  C08J2367/02 ,  C08J2401/26 ,  C08J2431/06 ,  C08J2435/02 ,  C08L1/26 ,  C08L35/00 ,  C08L35/02 ,  G02B5/3083 ,  C08L1/28

摘要： A resin composition including from 30 to 99 wt % of a cellulose-based resin represented by the following formula (1) and from 70 to 1 wt % of a fumaric acid ester polymer containing 30 mol % or more of a fumaric acid diester residue unit represented by the following formula (2); an optical compensation film using the same; and a production method of the optical compensation film. (wherein R1 to R3 represent a substituent having a carbon number of 1 to 12, and R4 and R5 represent an alkyl group having a carbon number of 1 to 12).

公开(公告)号：US20170348384A1

公开(公告)日：2017-12-07

申请号：US15687074

申请日：2017-08-25

申请人： Massachusetts Eye and Ear Infirmary

发明人： Benjamin S. Bleier

IPC分类号： A61K38/13 ,  A61K9/00 ,  A61K45/06 ,  A61K31/7048 ,  A61K31/65 ,  A61K31/58 ,  A61K31/573 ,  A61K31/56 ,  A61K31/55 ,  A61K31/545 ,  A61K31/496 ,  A61K31/473 ,  A61K31/4725 ,  A61K31/47 ,  A61K31/4545 ,  A61K31/43 ,  A61K31/4164 ,  A61K31/277 ,  A61L27/20 ,  A61L27/54

CPC分类号： A61K38/13 ,  A61K9/0043 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/496 ,  A61K31/545 ,  A61K31/55 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/65 ,  A61K31/7048 ,  A61K45/06 ,  A61L27/20 ,  A61L27/54 ,  A61K2300/00 ,  C08L1/28 ,  C08L5/04 ,  C08L5/08

摘要： Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.